Life sciences commercial teams are entering a new phase of customer engagement. The shift is no longer about adding another dashboard or chatbot to the CRM stack — it is about handing routine engagement decisions to agentic systems that can reason, act, and learn within guardrails set by compliance and medical affairs.
Why the CRM market is being redrawn right now
Two forces are colliding. First, Veeva’s move to end its reseller relationship with Salesforce and build its own Vault CRM has pushed pharma and medtech commercial organisations to re-evaluate platform roadmaps years earlier than planned. Second, generative and agentic AI capabilities are maturing fast enough that CRM vendors are racing to embed autonomous “agents” directly into rep-facing and HCP-facing workflows, rather than bolting AI on as a separate tool.
For commercial and IT leaders, the CRM decision is no longer only about data model and integrations. It is about which platform can host agentic workflows safely, at scale, across regulated markets.
What an agentic operating system actually changes
An agentic operating system sits across CRM, content, and data systems, coordinating multiple specialised agents rather than relying on one generic assistant. In a life sciences context, this typically plays out across four workflows:
Pre-call agent: synthesises HCP history, prescribing data, and medical content restrictions into a suggested next-best-action for the rep, with sources cited for compliance review.
Content orchestration agent: assembles approved, on-label content for a specific HCP conversation, pulling only from MLR-approved assets rather than generic templates.
Post-call agent: drafts the call report, updates CRM fields, and flags follow-up actions automatically, reducing rep administrative time.
Signal-detection agent: monitors adverse event mentions, competitor signals, or access barriers across channels and escalates to the right internal owner.
Industry case studies worth watching
Veeva vs Salesforce split: Veeva announced it will stop reselling on the Salesforce platform, forcing pharma and medtech clients onto Vault CRM by 2025-26 contract renewals. This has become the single biggest forcing function for CRM re-platforming conversations across the industry, independent of AI.
Salesforce and Accenture’s agentic push: The Salesforce-Accenture partnership highlighted in HBR’s sponsored coverage frames agentic operating systems as the answer to CRM market fragmentation, aiming to keep life sciences clients on Salesforce by embedding agent orchestration natively rather than through add-ons.
Field force productivity pilots: Several top-20 pharma companies have piloted AI copilots that draft call notes and suggest next-best actions, with internal reporting of meaningful reductions in non-selling administrative time for reps, though rigorous public benchmarking remains limited.
Medical affairs signal detection: Life sciences companies are increasingly using AI agents to scan digital channels for early adverse-event and off-label-use signals, routing them to pharmacovigilance teams faster than manual monitoring allowed.
What commercial and IT leaders should do now
Map agentic use cases to compliance risk tiers before choosing a platform. Not every workflow needs an autonomous agent — start with high-volume, low-risk tasks such as call-report drafting.
Treat the Veeva-Salesforce split as a forcing function, not a distraction. Use the mandatory migration window to redesign workflows rather than lift-and-shift the old CRM configuration.
Insist on auditability. Every agent recommendation shown to a rep or HCP-facing channel should be traceable to an approved source, with logs available for medical, legal, and regulatory review.
Pilot in one market before regional rollout. APAC markets, including Singapore, have distinct regulatory and language requirements that a single global agent configuration will not satisfy out of the box.
Life Sciences CRM Cheat Sheet
Salesforce is the #1 CRM platform in life sciences today, but Veeva is moving all commercial clients to Vault CRM by 2025-26, ending the Salesforce reseller model.
Agentic AI in CRM refers to autonomous agents that plan and execute multi-step tasks (e.g., drafting call reports), not just single-turn chatbot responses.
MLR (Medical, Legal, Regulatory) review remains mandatory for any AI-generated content shown to HCPs — agentic systems must pull only from pre-approved content libraries.
Rep administrative time is one of the most commonly cited targets for agentic CRM pilots, with call-report drafting and CRM data entry as the first automated workflows.
Vault CRM (Veeva) and Customer 360 for Life Sciences (Salesforce) are currently the two dominant enterprise platforms competing for pharma and medtech commercial teams.
Data residency and privacy rules (e.g., PDPA in Singapore, GDPR in the EU) directly affect where agentic CRM workloads and logs can be hosted and processed.
Auditability is non-negotiable: every agent-generated recommendation or message needs a traceable source and human sign-off path for compliance review.
APAC rollouts require localisation beyond translation — regulatory codes, HCP engagement norms, and language nuance all affect agent configuration by market.
The bottom line: the CRM platform decision in life sciences is now inseparable from the agentic AI roadmap. Leaders who treat these as two separate workstreams risk re-platforming twice — once for Veeva’s exit from Salesforce reselling, and again when they retrofit agents onto a system not designed to host them.
This analysis was informed in part by sponsored content from Salesforce and Accenture published in Harvard Business Review on the customer engagement moment in life sciences.
DR. AIDEA - Ideas In Life & healthcare 